Ranking Year:
# | Company Name | Region | Tech Topics | Total |
|---|
1 | Patent: 11 | |||
2 | Patent: 4 | |||
3 |  STARTUP | Health care,Fertility | Patent: 3 | |
4 | Patent: 2 | |||
5 | Patent: 1 |
Top 5 New Entrants companies in Nicotinamide mononucleotide
by Most Patent Filing In 5 Years in the United States in 2022
The Nicotinamide mononucleotide top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filing In 5 Years Nicotinamide mononucleotide New Entrants in the United States. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Nicotinamide mononucleotide ("NMN", "NAMN", and "β-NMN") is a nucleotide derived from ribose and nicotinamide. Like nicotinamide riboside, NMN is a derivative of niacin, and humans have enzymes that can use NMN to generate nicotinamide adenine dinucleotide (NADH).
Ranking:
Page generation time:
Dec 13 2025